MHC II Immunogenicity Shapes the Neoepitope Landscape in Human Tumors

The authors developed a method to identify peptide-major histocompatibility complex (pMHC) whose structural alignment facilitates T cell reaction. This method predicted neoepitopes for MHC II and MHC I that were responsive to checkpoint blockade when applied to >1,200 samples of various tumor types.